{"id":"963f7d3500a0","type":"article","url":"https://hartvaat.nl/2026/03/25/meta-analyse-glp-1-agonisten-voorkomen-hartfalen-in-type-2-diabetes-sterkste-eff/","title":"Meta-analyse: GLP-1-agonisten voorkomen hartfalen in type 2 diabetes, sterkste effect met semaglutide","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["bisoprolol","diabetes-type-2","empagliflozine","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","select-trial","semaglutide","soul-trial","tirzepatide"],"journal":"ESC heart failure","doi":"10.1093/eschf/xvag091","source_url":"https://doi.org/10.1093/eschf/xvag091","authors":["Keerthenan Raveendra","Tobin Joseph","Jing Kang","Ben Hurdus","Uther Cutting","Mohammad Haris","Tanina Younsi","Amaan Aslam","Mark Petrie","Marco Metra","Ramzi A Ajjan","Jianhua Wu","Chris P Gale","Ramesh Nadarajah"],"significance":8,"published":"2026-04-18","source_date":"2026-03-25","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/"],"congress":"","summary_en":"This meta-analysis of 12 placebo-controlled trials (n=95,023) found GLP-1 receptor agonists reduced heart failure events by 12% (NNT 238), and by 19% (NNT 167) in patients without baseline HF. Semaglutide specifically reduced HF events by 16% overall and by 31% in those without prior HF (NNT 80). Absolute benefits are modest but clinically relevant given the widespread use of GLP-1 therapy in type 2 diabetes and obesity management.","created":"2026-07-03T10:32:45Z","updated":"2026-07-03T13:31:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In een meta-analyse van 12 placebo-gecontroleerde trials (n=95.023) verlaagden GLP-1-receptoragonisten het risico op hartfalen-events met 12% (NNT 238) — en met 19% (NNT 167) bij patiënten zonder bestaande hartfalen. Semaglutide specifiek verlaagde HF-events met 16% en bij patiënten zonder HF met 31% (NNT 80). De absolute effecten zijn bescheiden, maar klinisch relevant gezien het brede gebruik van GLP-1-agonisten bij type 2 diabetes en obesitas. Cardiologen en internisten kunnen deze cijfers meenemen in de behandelafweging.","abstract_original":"BACKGROUND AND AIMS: Heart failure (HF) is a common sequela of diabetes and obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists may prevent HF events. This meta-analysis estimates absolute risk reduction (ARR) and number needed to treat (NNT) for GLP-1 receptor agonists to prevent one HF event in patients with type 2 diabetes and/or obesity, including in those without baseline HF. METHODS: The Medline, Embase, and Cochrane Central databases were searched to 04 April 2025 for placebo-controlled randomised controlled trials (RCTs) of GLP-1 receptor agonists in a type 2 diabetes and/or obesity indication with a prespecified heart failure event endpoint. Random effects meta-analysis using the Mantel-Haenszel Method was performed to synthesise risk ratios (RR), ARRs, and NNTs with 95% confidence intervals (CI). RESULTS: Twelve placebo-controlled RCTs involving 95 023 patients were included. GLP-1 receptor agonists reduced HF events by 12% (RR 0.88, 95% CI 0.82-0.95; ARR 0.42%, 95% CI 0.17%-0.62%; NNT 238, 95% CI 161-588), and, in those without baseline HF, by 19% (RR 0.81, 95% CI 0.72-0.90; ARR 0.60%, 95% CI 0.32%-0.89%; NNT 167, 95% CI 113-313). Semaglutide reduced the risk of HF events by 16% (RR 0.84, 95% CI 0.74-0.95; ARR 0.62%, 95% CI 0.19%-1.00%; NNT 161, 95% CI 100-526), and by 31% in those without baseline HF (RR 0.69, 95% CI 0.55-0.88; ARR 1.25%, 95% CI 0.48%-1.82%; NNT 80, 95% CI 55-208). CONCLUSIONS: GLP-1 receptor agonists have limited absolute benefit for preventing HF events in patients with type 2 diabetes and/or obesity, including in those without baseline HF. SYSTEMATIC REVIEW REGISTRATION: PROSPERO: CRD420251074882."}